Lactoferrin in Pediatric Chronic Kidney Disease and Its Relationship with Cardiovascular Risk

• Published in: Children (Basel) Vol. 11; no. 9; p. 1124
• Main Authors: Ho, Chun-Yi, Lu, Pei-Chen, Chen, Wei-Ling, Liao, Wei-Ting, Hsu, Chien-Ning, Tain, You-Lin
• Format: Journal Article
• Language: English
• Published: Switzerland MDPI AG 13.09.2024; MDPI
• Subjects: ambulatory blood pressure monitoring; biomarker; Biomarkers; Blood pressure; Body mass index; cardiovascular disease; Children; Cholesterol; chronic kidney disease; Chronic kidney failure; Congenital diseases; Creatinine; Diseases; Hyperlipidemia; Hypertension; Kidney diseases; lactoferrin; Lactoferrins; Measurement; Obesity; Overweight; Pediatrics; Plasma; Risk factors; Teenagers; Triglycerides; Ultrasonic imaging; Uric acid; Taiwan; United States > US; ambulatory blood pressure monitoring; cardiovascular disease; chronic kidney disease; children; lactoferrin; biomarker; hypertension
• ISSN: 2227-9067; 2227-9067
• DOI: 10.3390/children11091124

Pediatric CKD is associated with a high risk of cardiovascular disease (CVD). Early detection of subclinical CVD in childhood CKD can be achieved through various cardiovascular (CV) assessments, including carotid intima-media thickness (cIMT), ambulatory blood pressure monitoring (ABPM), and arterial stiffness indices. Lactoferrin (LF), a key functional glycoprotein found in breast milk, has been linked to several diseases and has potential as a biomarker. In our study of 102 children with CKD stages G1-G4, we explored the relationship between LF and CV risk markers. We found that LF concentration was not related to the severity or underlying causes of childhood CKD, but was positively correlated with overweight/obesity. Lower LF levels were correlated with increased cIMT and elevated arterial stiffness indices. Notably, abnormalities in ABPM profiles were observed in up to 60% of the children with CKD, with low LF levels linked to nighttime hypertension, nocturnal non-dipping, and ABPM abnormalities. In conclusion, LF shows promise as a biomarker for detecting subclinical CVD in children with CKD. Its potential utility in early detection could be instrumental in guiding timely interventions and improving long-term CV outcomes, although further research is needed to clarify the underlying mechanisms.